FDA Approves Durvalumab + Gemcitabine for Biliary Tract Cancer

 On September 2, 2022, the U.S Food and Drug Administration (FDA) durvalumab in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer. 

For more information, read the FDA announcement, and the AstraZeneca announcement. 

Posted 9/8/2022